Read what EORTC Director General Denis Lacombe has to say about the scientific complexity and economic cost of developing new cancer therapies, sac à dos kanken fjallraven pas cher nike air max 90 goedkoop which demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones,
SPECTAcolor, the EORTC’s premier Screening Platform for Efficient Clinical Trial Access for patients with colorectal cancer, enrolled its 100th patient in February 2014. “We are satisfied with the recruitment of patients with colorectal cancer and the analyses of their tumors. Chaussures Nike Pas Cher air max 1 pas cher Our efforts will lead to the… Read more »
SPECTAcolor is the first tumour Biobank and biomarker analysis platform to test molecular alterations in colorectal cancer patients whose illness is spreading fast. Solde Adidas The aim of the Biobank is to develop personalized cancer treatments tested in the course of clinical trials. Today, the EORTC is proud to announce the enrolment of the 100th… Read more »
This quarterly edition is dedicated to clinical trials and what they are all about. But first let us provide you with a brief update on the project patients’ status of enrollment. Today, the EORTC is proud to announce that 208 patients have been enrolled in the biobank to be entered in biomarker-led clinical trials. Good… Read more »
Check the last article in the Clinical Oncology News (January 2012) about the dynamism of European Researchers in colorectal cancer clinical research.